Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/08—Solutions
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
  • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
  • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
  • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
  • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
  • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
  • A61K31/404—Indoles, e.g. pindolol
  • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
  • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
  • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
  • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/0012—Galenical forms characterised by the site of application
  • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/04—Centrally acting analgesics, e.g. opioids
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Definitions

• the present invention relates to novel and highly stable injectable pharmaceutical compositions comprising at least one cyclooxygenase-II enzyme (COX-II) inhibitor or non-steroidal anti-inflammatory drug (NSAID) or COX/LOX inhibitor, or its tautomeric forms, analogues, isomers, polymorphs, solvates, prodrugs or salts thereof as active ingredient suitable for parenteral administration preferably by intramuscular
• COX-II cyclooxygenase-II enzyme
• NSAID non-steroidal anti-inflammatory drug
• COX/LOX inhibitor COX/LOX inhibitor
• the analgesic and anti-inflammatory injectable compositions of the present invention are very useful in mammals particularly in humans for the treatment of acute painful conditions like one or more of post-operative trauma, pain associated with cancer, sports injuries, migraine headache, neurological pain and pain associated with sciatica
• Non-steroidal anti-inflammatory drugs '(NSAIDs) and cyclooxygenase-II enzyme (COX-Il) ' inhibitors 1 ' are 1 1 i ⁇ l ! - general : highly 1 ⁇ hydrophobic compounds and readily precipitate even 4 in 'the presence 1 bf 'minor amounts of water. Hence it is very difficult to formulate ⁇ such compounds into injectable compositions for intramuscular or intravenous use.
• NSAIDs such as nimesulide, ketorolac, diclofenac, ibuprofen and naproxen, and COX- II inhibitors" in 'parenteral forrni 1 capable of instant 'therapeutic action are extremely desirable.
• a suitable', safe 1 and non-toxic carrier/vehicle is required in which these drugs are soluble. Due to the physico-chemical properties of these groups of compounds, the NSAIDs or the COX-II inhibitors are poorly soluble in water hence presenting a difficulty in formulating these drugs in the parenteral fprrn.
• injectable compositions comprising of NSAIDs such as nimesulide.
• An injectable formulation of nimesulide has been reported in PCT Patent No. WO 95/34533 that discloses the utilization of a salt form of nimesulide with L-lysine which is in turn further complexed with cyclodextrins that may be dissolved in water to give an injectable preparation.
• the maximum solubility achieved by this injectable composition was reported to be 2.4 mg/ml, which is not sufficient for intramuscular administration, as it would require very large volumes to administer therapeutic doses.
• Nimesulide is a potent non-steroidal anti-inflammatory (NSAID) drug, presently used in the treatment of painful inflammatory conditions due to rheumatoid arthritis, which also possesses antipyretic activity. Compared to other NSAIDs, nimesulide has a better therapeutic ratio, low gastro toxicity and generally good tolerability. Nimesulide is a strongly hydrophobic substance that is practically insoluble in water (solubility in water at room temperature being 0.01 mg/ml). Since nimesulide is insoluble in water and in a large number of non-toxic solvents specifically those which are approved for parenteral use, it becomes highly difficult to formulate it into solutions suitable for parenteral administration via intramuscular or intravenous route.
• NSAID non-steroidal anti-inflammatory
• NSAIDs such as diclofenac, ibuprofen, indomethacin, and naproxen also offer a lot of difficulty in making them into injectable compositions using approved excipients and the permissible concentrations in which they are approved for parenteral use.
• Parenteral compositions particularly comprising cyclooxygenase-II inhibitors such as rofecoxib or valdecoxib are highly unstable upon storage due to the tendency of such drugs to precipitate out, and hence it becomes difficult to obtain a homogeneous solution for parenteral administration during the shelf life of such products. It is known and well accepted that parenteral administration of drugs for the treatment of painful inflammatory conditions, is more effective than other routes of administration, since the drug enters the circulation directly and promptly manifests its therapeutic effect.
• compositions containing propofol suitable for parenteral administration to produce anesthesia in warm-blooded animals as mixtures of propofol with surfactants such as Cremophor® RH40, Cremophor® EL, and Tween® 80 in an aqueous medium that may also contain ethanol or other pharmaceutically acceptable ingredients.
• surfactants such as Cremophor® RH40, Cremophor® EL, and Tween® 80 in an aqueous medium that may also contain ethanol or other pharmaceutically acceptable ingredients.
• 4,794, 1 17 claims a process for solubilizing indomethacin in water consisting essentially of dissolving an anti-inflammatory amount of indomethacin in a solubilizing amount of at least one polyethylene glycol having a molecular weight of 300 to 700 and dissolving the resulting solution in a solubilizing amount of an aqueous medium buffered in a pH range of 4.5 to 8 especially intended for the external use.
• US Patent No. 4,798,846 discloses sterile propofol compositions containing 1% to 2% propofol alone or dissolved in oil such as arachis oil or ethyl oleate. These formulations are stabilized with surfactants.
• 5,858,999 discloses a sterile aqueous pharmaceutical composition for parenteral administration which comprises about 0.9 to about 90 mg/ml of a lazaroid or a pharmaceutically acceptable salt thereof, about 0.002 to about 2.0M citrate, upto about 80% of a cosolvent selected from the group consisting of propylene glycol, polyethylene glycol, glycerol, ethanol, dimethylsulfoxide, dimethylacetamide, dimethyl isosorbide, N-methyl-2-pyrrolid ⁇ ne and water at a pH of about 2.4 to about 3.5. These compositions use very high concentrations of cosolvents.
• US Patent No. 5,688,829 assigned to the applicant of the present invention discloses a therapeutic injectable analgesic pharmaceutical composition for intra-muscular administration comprising essentially nimesulide in a parenteral absorption enhancing base comprising dimethyiacelamide, benzyl benzoate and ethyl oleate.
• the said composition uses lipophilic solvents that are oily in nature to solubilize nimesulide, which does not allow administration of the injectable via the intravenous route.
• 6,451,302 assigned to the same applicant describes an injectable water- miscible composition
• nimesulide benzyl alcohol
• a substance selected from the group consisting of dimethylacctamide, dimethylformamide, dimethylsulphoxide, and N-methyl pyrrolidone and a glycol selected from the group consisting of polyethylene glycol (PEG 200 to 600), propylene glycol, hexylene glycol, butylene glycol, and polyethylene glycol 660 hydroxy stearate.
• PEG 200 to 600 polyethylene glycol
• propylene glycol propylene glycol
• hexylene glycol hexylene glycol
• butylene glycol butylene glycol
• polyethylene glycol 660 hydroxy stearate polyethylene glycol
• US Patent No. 6,589,973 pertains to a clear, stable novel pharmaceutical preparation of selective COX-II inhibitors in the parenteral form for the treatment of pain and inflammatory conditions arising because of cyclooxygenase-II activity.
• the pharmaceutical preparation of COX-II inhibitors comprise of selective COX-II inhibitors such as celecoxib, rofecoxib and their analogs dissolved in a selective isosorbide type solvent.
• EP Patent No. 1228757 relates to stable pharmaceutical solutions suitable for parenteral administration of nimesulide consisting of 80% glycerol formal, 15% ethanol and 5% water and/or 75% glycerol formal, 10% ethanol, 10% propylene glycol and 5% water.
• PCT Publication No. WO 2000072884 describes a novel pharmaceutical composition of nimesulide and 2,5-di-0-methyl-l,4:3,6-dianhydro-D-glucitol with or without water, optionally containing one or more diluents which can be used for IWIM administration or oral or topical formulations.
• 20030078266 specifically relates to a pharmaceutical composition
• a pharmaceutical composition comprising in powder form, at least one water-soluble therapeutic agent selected from selective COX-2 inhibitory drugs and prodrugs and salts thereof, in a therapeutically effective total amount constituting about 30% to about 90% by weight, a parenterally acceptable buffering agent in an amount of about 5% to about 60% by weight, and other parenterally acceptable excipient ingredients in a total amount of zero to about 10% by weight, of the composition; said composition being reconstitutable in a parenterally acceptable solvent liquid to form an injectable solution.
• compositions intended for parenteral use should be nontoxic and should be preferably present in low concentrations.
• Most of the existing patent and literature references describe parenteral compositions, which comprise very high concentrations of solvents that are primarily not approved for parenteral use and also are unstable during storage.
• compositions comprising COX-II inhibitors or NSAIDs in which the latter are substantially soluble, and compositions those are devoid of such aforementioned problems and which could remain stable throughout the shelf life of the product.
• the inventors of the present invention have done extensive research and conducted several experiments using different non-toxic solvents and discovered that their combination in various concentrations along with suitable buffers and alkalizing agents results in a highly solubilized system suitable for parenteral administration in which the COX-II inhibitors and/or NSAIDs are soluble and which are also stable during the storage of the product thus demonstrating a significant advancement over the prior art.
• It is an objective of the present invention to provide novel injectable pharmaceutical compositions comprising at least one COX-II inhibitor or NSAID or COX/LOX inhibitor, or its tautomeric forms, analogues, isomers, polymorphs, solvates, prodrugs, or salts thereof as active ingredient and a solvent system comprising "a mixture of glycols; optionally with other pharmaceutically acceptable excipients.
• It is an objective of the present invention to provide novel injectable pharmaceutical compositions comprising at least one COX-II inhibitor or NSAID or COX/LOX inhibitor, or its tautomeric forms, analogues, isomers, polymorphs, solvates, prodrugs, or salts thereof as active ingredient; a solvent system comprising a mixture of glycols; at least one alkalizing agent; optionally with other pharmaceutically acceptable excipients.
• It is an objective of the present invention to provide novel injectable pharmaceutical compositions comprising at least one COX-II inhibitor or NSAID or COX/LOX inhibitor, or its tautomeric forms, analogues, isomers, polymorphs, solvates, prodrugs, or salts thereof as active ingredient; a solvent system comprising a mixture of glycols; at least one alkalizing agent; at least one buffering agent; optionally with other pharmaceutically acceptable excipients.
• compositions comprising a NSAID preferably nimesulide as active ingredient, a solvent system comprising a mixture of glycols, at least one alkalizing agent, at least one buffering agent, optionally with other pharmaceutically acceptable excipients.
• It is another objective of the present invention to provide novel injectable pharmaceutical compositions comprising at least one COX-II inhibitor or NSAID or COX/LOX inhibitor, or its tautomeric forms, analogues, isomers, polymorphs, solvates, prodrugs, or salts thereof as active ingredient and a solvent system comprising a mixture of glycols; optionally with other pharmaceutically acceptable excipients, additionally comprising one or more other pharmaceutically acceptable active ingredient(s).
• IM intramuscular
• IV intravenous
• It is yet another objective of the present invention to provide a process for preparation of a novel injectable pharmaceutical compositions comprising at least one COX-II inhibitor or NSAID or COX/LOX inhibitor, or its tautomeric forms, analogues, isomers, polymorphs, solvates, prodrugs, or salts thereof as active ingredient and a solvent system comprising a mixture of glycols; optionally with other pharmaceutically acceptable excipients, which comprises of the following steps: i) adding the active ingredient(s) to the mixture of glycols followed by mixing, ii) optionally adding other pharmaceutically acceptable excipients and mixing to produce the injectable composition.
• It is a still further objective of the present invention to provide a process for preparation of a novel injectable pharmaceutical compositions comprising at least one COX-II inhibitor or NSAID or COX/LOX inhibitor, or its tautomeric forms, analogues, isomers, polymorphs, solvates, prodrugs, or salts thereof as active ingredient and a solvent system comprising a mixture of glycols; optionally with other pharmaceutically acceptable excipients, additionally comprising one or more buffering agent(s) and/or alkalizing agent(s), which comprises of the following steps: i) adding one or more buffering agent(s) to the mixture of glycols and mixing to obtain a homogeneous mixture, ii) adding the active ingredient(s) to the mixture followed by mixing, iii) adding alkalizing agent(s) followed by mixing, iv) adding the buffering agent(s) with mixing to obtain a homogeneous mixture, v) optionally adjusting the pH of the mixture to an alkaline pH by adding al
• compositions of the present invention are particularly useful for the treatment of one or more acute painful conditions such as post-operative trauma, pain associated with cancer, sports injuries, migraine headache, neurological pain and pain associated with sciatica and spondylitis, or chronic painful conditions, and/or other associated disorders.
• acute painful conditions such as post-operative trauma, pain associated with cancer, sports injuries, migraine headache, neurological pain and pain associated with sciatica and spondylitis, or chronic painful conditions, and/or other associated disorders.
• the present invention describes novel injectable pharmaceutical compositions comprising at least one COX-II inhibitor or NSAID or COX/LOX inhibitor, its tautomeric forms, analogues, isomers, polymorphs, solvates, prodrugs, or salts thereof as active ingredient.
• the active ingredient is a NSAID, more preferably nimesulide.
• the compositions of the present invention additionally comprise a solvent system comprising a mixture of glycols, optionally with other pharmaceutically acceptable excipients.
• novel injectable pharmaceutical compositions of the present invention comprise additionally at least one alkalizing agent(s) and/or at least one buffering agent(s).
• the novel injectable pharmaceutical composition comprises at least one COX-II inhibitor or NSAID or COX/LOX inhibitor or its tautomeric forms, analogues, isomers, polymorphs, solvates, prodrugs, or salts or thereof as active ingredient from about 0.1% to about 80% w/v of the composition and a solvent system comprising a mixture of glycols from about 1% to about 80% v/v of the composition; optionally with other pharmaceutically acceptable excipients.
• the composition of the present invention additionally comprise at least one alkalizing agent from about 0.2% to about 60% v/v of the composition and/or at least one buffering agent from about 2% to about 80% v/v of the composition.
• the present invention provides novel injectable pharmaceutical compositions comprising nimesulide as active ingredient, a solvent system comprising a mixture of glycols, at least one alkalizing agent, at least one buffering agent, optionally with other pharmaceutically acceptable excipients.
• the injectable compositions comprising COX-II inhibitor or NSAID or COX/LOX inhibitor can be prepared using a mixture of different non-toxic solvents in various concentrations along with suitable buffers and alkalizing agents. These compositions are clear, odorless, highly stable, non-toxic and homogeneous and are therefore suitable for parenteral administration.
• the injectable compositions are suitable particularly for administration by intravenous (IV) or intramuscular (IM) route.
• the solubilization techniques used to solubilize the poorly soluble COX-II inhibitors or NSAIDs or COX/LOX inhibitor are based on cosolvation and/or pH modification techniques.
• the compositions of the present invention are highly stable, preferably in the pH range of about 7.5 to 1 1.5, more preferably in the pH range of about 9.0 to 1 1.0.
• the active ingredient useful in the present invention are preferably NSAIDs selected from but not limited to a group comprising nimesulide, nabumetone, tapoxalin, diclofenac, flosulide ibuprofen, indomethacin, naproxen, and the like, their tautomeric forms, analogues, isomers, polymorphs, solvates, prodrugs, or salts thereof or COX-II inhibitors selected from but not limited to a group comprising celecoxib, rofecoxib, valdecoxib, etoricoxib, parecoxib, itacoxib, deracoxib and the like or their tautomeric forms, analogues, isomers, polymorphs, solvates, prodrugs or salts thereof.
• NSAIDs selected from but not limited to a group comprising nimesulide, nabumetone, tapoxalin, diclofenac, flosulide
• the active ingredient of the present invention belongs to the category of COX/LOX (cyclooxygenase/lipooxygenase) inhibitor such as licofelone.
• the active ingredient is present in the micronized form.
• the novel injectable pharmaceutical compositions comprising at least one COX-II inhibitor or NSAID or COX/LOX inhibitor, or its tautomeric forms, analogues, isomers, polymorphs, solvates, prodrugs, or salts thereof as active ingredient and a solvent system comprising a mixture of glycols; optionally with other pharmaceutically acceptable excipients, additionally comprises one or more other pharmaceutically acceptable active ingredient(s).
• compositions useful in the present invention is any active agent, which can be combined with a COX-II inhibitor or a NSAID or COX/LOX inhibitor, known in the art such as acetaminophen, serratiopeptidase, antibacterial agents, CNS agents, CVS agents, or the like.
• the mixture of glycols used to make the solvent system is polyethylene glycol (PEG) selected from but not limited to a group comprising PEG 200, PEG 300, PEG 400, PEG 600 and PEG 700, or mixtures thereof; and propylene glycol.
• the solvent system comprises a mixture of PEG 400 and propylene glycol.
• the alkalizing agent used is an inorganic base or an organic base or a combination of both.
• the alkalizing agent used is selected from but not limited to a group comprising inorganic bases such as sodium hydroxide, potassium hydroxide, calcium hydroxide, magnesium hydroxide, calcium carbonate, magnesium carbonate, magnesium oxide, and the like, or mixtures thereof; and/or organic bases such as meglumine, triethanolamine, diethanolamine and the like, or mixtures thereof.
• the alkalizing agent is an inorganic base such as sodium hydroxide or potassium hydroxide.
• the alkalizing agent is preferably used as an aqueous (water) solution, prepared by dissolving the said agent in water. The quantity of the said agent and volume of water in which the agent is dissolved is used so as to obtain desired concentration of the agent.
• the buffering agent used in the present invention is preferably an alkaline buffering agent selected from but not limited to a group comprising glycine buffer, lysine buffer, phosphate buffer, acetate buffer, and the like, or mixtures thereof, preferably having a pH range of about 7.2 to about 12.5.
• glycine buffer is used as the buffering agent in the -compositions of the present invention.
• glycine buffer having pH of about 8.3 to about 1 1.3 is used as the buffering agent.
• the buffering agent is preferably used as an aqueous (water) solution, prepared by dissolving the desired compound(s) in water. The quantity of the desired compound(s) and volume of water in which the desired compound(s) is dissolved is used so as to obtain desired concentration and pH of the agent.
• compositions ofthe present invention are selected from but not limited to the group of excipients generally known to persons skilled in the art e.g. vehicles, bulking agents, stabilizers, preservatives, surfactants, hydrophilic polymers, solubility enhancing agents such as glycerine, various grades of polyethylene oxides, beta-cyclodextrihs like sulfobutylether-beta-cyclodextrin, transcutol and glycofurol, tonicity adjusting agents, local anesthetics, pH adjusting agents, antioxidants, osmotic agents, chelating agents, viscosifying agents, wetting agents, emulsifying agents, acids, sugar alcohol, reducing sugars, non-reducing sugars and the like, or mixtures thereof.
• the Pharmaceutically acceptable excipient(s) is used in an amount of about 0.1% to about 70% w/v or v/v of the composition.
• the vehicles suitable useful in the present invention can be selected from but not limited to a group comprising dimethylacetamide, dimethylformamide, dimethylsulphoxide, N-methyl pyrrolidone, benzyl benzoate, benzyl alcohol, ethyl oleate, polyoxyethylene glycolated castor oils (Cremophor® EL), polyethylene glycol such as those having molecular weight of about 200 to 6000, propylene glycol, hexylene glycols, butylene glycols and glycol derivatives such as polyethylene glycol 660 hydroxy stearate (Solutrol® HS 15) and the like, or mixtures thereof.
• a group comprising dimethylacetamide, dimethylformamide, dimethylsulphoxide, N-methyl pyrrolidone, benzyl benzoate, benzyl alcohol, ethyl oleate, polyoxyethylene glycolated castor oils (Cremophor® EL), polyethylene glycol such
• the compositions additionally comprises an antimicrobial preservative such as benzyl alcohol preferably at a concentration of about 0.001% to about 5.0% w/w of the composition.
• an antimicrobial preservative such as benzyl alcohol preferably at a concentration of about 0.001% to about 5.0% w/w of the composition.
• the composition additionally comprises a conventionally known antioxidant selected from but not limited to a group comprising ascorbyl palmitate, butyl hydroxy anisole, butyl hydroxy toluene, propyl gal late, ⁇ -tocopherol and the like, or mixtures thereof.
• a conventionally known antioxidant selected from but not limited to a group comprising ascorbyl palmitate, butyl hydroxy anisole, butyl hydroxy toluene, propyl gal late, ⁇ -tocopherol and the like, or mixtures thereof.
• compositions of the present invention are highly stable.
• the novel compositions of the present invention may be diluted with suitable diluting fluids known to the art to prepare a solution or ' dispersion or infusion before administration.
• suitable diluting fluids known to the art to prepare a solution or ' dispersion or infusion before administration.
• the novel compositions of the present invention are highly stable and compatible with different diluting fluids such as demineralized (DM) water, dextrose 5% w/v, sodium chloride 0.9% w/v or mixtures thereof. These fluids can be employed during the manufacture of the composition or can be used for diluting the composition before administration.
• DM demineralized
• the composition is stable for 5 hrs upto 1 : 150 dilution and for 48 hrs up to 1 :5 dilution with DM water; for 2 hrs upto 1 : 150 dilution and for 4 hrs upto 1 :3 dilution with dextrose 5.0% solution; and for 24 hrs upto 1 : 150 dilution and for 48 hrs upto 1 : 100 dilution with 0.9% NaCl solution, particularly at room temperature.
• compositions of the present invention are preferably filled into ampoules.
• Compatibility study on nimesulide injection (content of one ampoule) with different infusion solutions were performed to study the physical stability (during intravenous infusion) of the injection after diluting with infusion solutions.
• Most of the infusion solutions possess pH in acidic range (e.g. Normal saline, about 6.2; Ringer lactate solution, about 6.5 and Dextrose 5% w/v, about 5.5).
• Admixing with infusion solution for known injections comprising a COX-II inhibitor or NSAID or COX/LOX inhibitor results into saturation and thus crystallization. This is not desirable for a solution if diluted as such since such solution is meant for parenteral administration.
• ethanol and/or dimethylacetamide (DMA) can also be added to the compositions of the present invention to further enhance the solubility of the active ingredient(s).
• Example- 1 Stability study was conducted on the composition stated in Example- 1 herein. Long term (at controlled room temperature i.e. 25°C), intermediate (at 30 0 C and 70% RH), accelerated (at 40 0 C and 75% RH), and stress (at 60 0 C) stability studies were performed on the product and samples were analyzed including the controlled samples kept at freezing conditions (at 2-8 0 C). The product was found to be stable for more than six months at each of the above conditions and it did not show any stability issues relating to physical changes like particulate matter, crystallization and color change or chemical changes such as change in potency or presence of any degradation product.
• the nimesulide injection is formulated preferably as an aqueous injection meant for dilution with infusion solutions particularly in case of IV administration.
• Nimesulide possess pH dependent solubility i.e. nimesulide is soluble at alkaline pH and practically insoluble at acidic pH.
• a solvent system comprising a mixture of solvents (particularly glycols) optionally along with a pH adjusting system has been adopted to prepare a stable formulation in the present invention.
• Nimesulide IM injection Label claim: Each 3 ml contains 100 mg of nimesulide
• No toxicity symptoms were observed at dose level of 41.6 mg/kg of nimesulide injection and with 2.5 ml/kg placebo injection in mice.
• Mice injected with a dose of 83.3, 166.67, 208.33 or 250 mg/kg showed toxicity symptoms.
• the " mortality rates of 40%, 80%, and 100% were observed at dose level of 166.67 mg/kg, 208.33 mg/kg, and 250 mg/kg respectively.
• the LD 50 of the nimesulide injection when administered intramuscularly was found to be 173.78 mg/kg.
• Nimesulide IV injection of the present invention when tested (at blood to test sample ratio of 1 : 10) on Rat packed red blood cells (citrated) showed comparative fractions of healthy cells as compared to CALMPOSE®, FORTWIN®, NIMOVET® and VOVERAN®.
• the perivenous tolerance following a single intravenous administration of Nimesulide IV injection 100 mg/3 ml of the present invention against a placebo composition was studied in rabbits. The study showed that the animals injected intravenously with Nimesulide IV injection of the present invention or the placebo did not show any signs of local irritation at the site of injection in the right ears.
• Nimesulide IV injection of the present invention was carried out in rabbits.
• Nimesulide IV injection each 2 ml ampoule containing 75 mg nimesulide, was used.
• a dose of 3.75 mg/kg body weight of rabbit equivalent to human dose of 75 mg/60kg were administered by IV route , via marginal ear vein of rabbits and blood sampling was done at 0, 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, and 24 hour intervals, and the plasma samples were analyzed for nimesulide by LC-MS/MS.
• Table-l Pharmacokinetic profile of Nimesulide injection in rabbits
• the process for preparation of a novel injectable pharmaceutical compositions comprising at least one COX-II inhibitor or NSAID or COX/LOX inhibitor, or its tautomeric forms, analogues, isomers, polymorphs, solvates, prodrugs, or salts thereof as active ingredient and a solvent system comprising a mixture of glycols; optionally with other pharmaceutically acceptable excipients, which comprises of the following steps: i) adding the active ingredient(s) to the mixture of glycols followed by mixing, ii) optionally adding other pharmaceutically acceptable excipients and mixing to produce the injectable composition.
• the process for preparation of a novel injectable pharmaceutical compositions comprising at least one COX-II inhibitor and/or NSAID or COX/LOX inhibitor, or its tautomeric forms, analogues, isomers, polymorphs, solvates, prodrugs, or salts thereof as active ingredient and a solvent system comprising a mixture of glycols; optionally with other pharmaceutically acceptable excipients, additionally comprising one or more buffering agent(s) and/or alkalizing agent(s), which comprises of the following steps: i) adding one or more buffering agent(s) to the mixture of glycols and mixing to obtain a homogeneous mixture, ii) adding the active ingredient(s) to the mixture followed by mixing, iii) adding alkalizing agent(s) followed by mixing, iv) adding the buffering agent(s) with mixing to obtain a homogeneous mixture, v) optionally adjusting the pH of the mixture to an alkaline pH by adding alkalizing agent(s) to produce the
• the process as described herein comprises the active ingredient selected from a group comprising of at least one COX-II inhibitor or NSAID or
• COX/LOX inhibitor or its tautomeric forms, analogues, isomers, polymorphs, solvates, prodrugs, or salts thereof, optionally with one or more additional active ingredient(s) that can be combined with a COX-II inhibitor or NSAID known to art.
• a COX-II inhibitor or NSAID known to art.
• NSAID is nimesulide or its tautomeric forms, analogues, isomers, polymorphs, solvates, prodrugs, or salts thereof.
• compositions of the present invention are provided.
• the analgesic and anti-inflammatory injectable compositions of the present invention are useful for the treatment of acute painful conditions like post-operative trauma, pain associated with cancer, sports injuries, migraine headache, neurological pain and pain associated with sciatica and spondylitis, and the like, in mammals particularly in humans and animals, more particularly in humans.
• the present invention provides a method of using the novel injectable pharmaceutical composition, which comprises administering to a patient in need thereof an effective amount of the composition.
• the present invention provides a method of using the injectable pharmaceutical composition preferably for the treatment of acute and/or chronic painful conditions in mammals particularly mammals, including a variety of painful and inflammatory conditions like postoperative pain, primary dysmenorrhea and painful osteoarthritisand/or other associated disorders such as inflammation, fever, allergy, or the like.
• the present invention provides a method of using the injectable pharmaceutical composition particularly for the treatment of acute painful conditions, wherein such condition is one or more of post-operative trauma, pain associated with cancer, sports injuries, migraine headache, neurological pain and pain associated with sciatica and spondylitis.
• the use of the compositions of the present invention for the preparation of medicament for the treatment of acute painful conditions wherein such condition is one or more of post-operative trauma, pain associated with cancer, sports injuries, migraine headache, neurological pain and pain associated with sciatica and spondylitis, and/or chronic painful conditions, and/or painful and inflammatory conditions like postoperative pain, primary dysmenorrhea and painful osteoarthritis and/or other associated disorders such as inflammation, fever, allergy, or the like.
• Example-1 Nimesulide Injection (100 mg/3 ml)
• Example-2 Diclofenac Injection (75 mg/3 ml)
• Example-9 Nimesulide Injection (100 mg/3 ml)
• Nimesulide 3.34 gm 5 Potassium hydroxide (KOH) solution 5.6 % w/v 1 1 .20 ml
• Procedure i) Take specified quantity (20.00 ml) of PEG-600 into a vessel. iJX Add Propylene glycol (10.00 ml) to step (i) with continuous stirring. iii) Add about 50.0 ml of the Phosphate Buffer pH 7.2 to the step (ii) with continuous stirring to form a homogeneous mixture, iv) Add weighed amount of Nimesulide (3.34 gm) passed through #60 mesh to the step (iii) with continuous stirring.
• Example-10 Nimesulide Injection (100 mg/3 ml)
• Example-12 Licofelone injection (100 mg/3 ml):
• Example-13 Parecoxib injection (50 mg/2 ml):
• Example-14 Diclofenac Sodium injection (75 nig/2 ml):
• Example-15 Ibuprofen injection (200 mg/2 ml):

Landscapes

• Health & Medical Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• General Health & Medical Sciences (AREA)
• Veterinary Medicine (AREA)
• Medicinal Chemistry (AREA)
• Public Health (AREA)
• Pharmacology & Pharmacy (AREA)
• Epidemiology (AREA)
• Chemical Kinetics & Catalysis (AREA)
• General Chemical & Material Sciences (AREA)
• Engineering & Computer Science (AREA)
• Oil, Petroleum & Natural Gas (AREA)
• Pain & Pain Management (AREA)
• Proteomics, Peptides & Aminoacids (AREA)
• Organic Chemistry (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Biomedical Technology (AREA)
• Dermatology (AREA)
• Neurology (AREA)
• Rheumatology (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Neurosurgery (AREA)
• Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Medicinal Preparation (AREA)
• Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Applications Claiming Priority (2)

Publications (1)

Family

ID=36917368

Family Applications (1)

Country Status (15)

Families Citing this family (20)

Family Cites Families (5)

• 2006
  • 2006-05-25 MX MX2007014862A patent/MX2007014862A/es not_active Application Discontinuation
  • 2006-05-25 BR BRPI0611170-0A patent/BRPI0611170A2/pt not_active IP Right Cessation
  • 2006-05-25 JP JP2008513009A patent/JP2008542260A/ja not_active Withdrawn
  • 2006-05-25 CN CNA2006800250937A patent/CN101217939A/zh active Pending
  • 2006-05-25 KR KR1020077030585A patent/KR20080016689A/ko not_active Application Discontinuation
  • 2006-05-25 AU AU2006250765A patent/AU2006250765A1/en not_active Abandoned
  • 2006-05-25 EA EA200702646A patent/EA200702646A1/ru unknown
  • 2006-05-25 EP EP06756263A patent/EP1895983A2/de not_active Withdrawn
  • 2006-05-25 RS RSP-2007/0461A patent/RS20070461A/sr unknown
  • 2006-05-25 CA CA002609242A patent/CA2609242A1/en not_active Abandoned
  • 2006-05-25 WO PCT/IN2006/000177 patent/WO2006126214A2/en active Application Filing
  • 2006-05-25 ZA ZA200711068A patent/ZA200711068B/xx unknown
• 2007
  • 2007-12-14 NO NO20076468A patent/NO20076468L/no not_active Application Discontinuation
  • 2007-12-19 CR CR9616A patent/CR9616A/es not_active Application Discontinuation
  • 2007-12-21 TN TNP2007000482A patent/TNSN07482A1/fr unknown

Non-Patent Citations (1)

Also Published As

Similar Documents

Legal Events